EmbB and EmbC Regulate the Sensitivity of to Echinomycin

Jing He,Yamin Gao,Jingyun Wang,H.M. Adnan Hameed,Shuai Wang,Cuiting Fang,Xirong Tian,Jingran Zhang,Xingli Han,Yanan Ju,Yaoju Tan,Junying Ma,Jianhua Ju,Jinxing Hu,Jianxiong Liu,Tianyu Zhang
DOI: https://doi.org/10.1101/2024.02.25.578291
2024-02-25
Abstract:Treatment of (Mab) infection is a major challenge due to its intrinsic resistance to most available drugs. It is thus imperative to find new anti-Mab drugs. In this study, we investigated the activity and intrinsic resistance mechanism of echinomycin (ECH) against Mab. ECH is active against Mab (MIC: 2 µg/mL). The gene knockout strain (Mab ) showed hyper-sensitive to ECH (MIC: 0.0078-0.0156 µg/mL). The MICs of ECH-resistant strains screened based on the Mab strain were 0.25-1 µg/mL. Mutations were found in the EmbB, including Asp306Ala, Asp306Asn, Arg350Gly, Val555Ile, and Gly581Ser, which led to increased resistance to ECH when overexpressed in Mab individually (0.25-0.5 µg/mL). The EmbB mutants edited by the CRISPR/Cpf1 system became more resistant to ECH (MIC: 0.25-0.5 µg/mL). The permeability of gene-edited and overexpressed Mab strains was reduced, as shown by the ethidium bromide accumulation assay, but it was still significantly higher than that of the parent Mab. To summarize, our study demonstrates that ECH has a strong anti-Mab activity and confirms that EmbB and EmbC are related to the sensitivity of Mab to ECH. EmbB mutation may partially compensate for the function of EmbC.
Microbiology
What problem does this paper attempt to address?